About Luoxin Pharmaceutical Group
Luoxin Pharmaceutical Group was founded in 2006 in Linyi, China, within the pharmaceutical sector. Operations encompass research and development of drug formulations across therapeutic fields such as gastroenterology, pediatrics, respiratory, and oncology. Manufacturing facilities are utilized for production, while distribution networks facilitate market access. Standards for drug safety and vigilance are consistently applied throughout activities.
- Headquarter Linyi, China
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website luoxin.cn
- Social LinkedIn
- Acquired by Ally Bridge Group (Mar 2017)
- Legal Name Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A
- Annual Revenue$322.81 M (USD)-14.6as on Dec 31, 2025
- Net Profit-$41.22 M (USD)70.11as on Dec 31, 2025
- EBITDA$6.87 M (USD)0as on Dec 31, 2025
- Investors
- Acquired byAlly Bridge Group
(Mar 2017)
Investors in Luoxin Pharmaceutical Group
Luoxin Pharmaceutical Group has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China |
Investor details for Luoxin Pharmaceutical Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Luoxin Pharmaceutical Group
Luoxin Pharmaceutical Group is a publicly listed company on the SZSE with ticker symbol 002793 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 2016
- Listed onSZSE: 002793
- Listed entityLuoxin Pharmaceuticals Group Stock Co., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE1000026S7
- Share price4.89 CNY (+3.16% on the day) · 2026-10-09
- Market capitalisation5,293,694,665.00 CNY
- EPS (diluted, trailing year)-0.24 CNY
- Volume (last session)29,724,403
Financials of Luoxin Pharmaceutical Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.26B CNY | -288.6M CNY | 48.1M CNY |
| 2024 | 2.64B CNY | -965.5M CNY | -577.1M CNY |
| 2023 | 2.36B CNY | -661.1M CNY | -267.6M CNY |
| 2022 | 3.57B CNY | -1.22B CNY | -1.33B CNY |
| 2021 | 6.42B CNY | 406.1M CNY | 731.8M CNY |
Detailed financial statements for Luoxin Pharmaceutical Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Luoxin Pharmaceutical Group
3 dated milestones of Luoxin Pharmaceutical Group across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Luoxin Pharmaceutical Group is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Ally Bridge Group.
Web traffic of Luoxin Pharmaceutical Group
The website of Luoxin Pharmaceutical Group (luoxin.cn) receives about 4K visits a month and ranks #3,674,591 among all websites worldwide, #4,719 in Biotechnology and Pharmaceuticals.
- Monthly visits4K
▼ 17.2% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,674,591
among all websites
- Category rank#4,719
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.0
- Average visit18 sec
- DevicesDesktop 43% · Mobile 57%
Latest news on Luoxin Pharmaceutical Group
Complete news archive for Luoxin Pharmaceutical Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Luoxin Pharmaceutical Group
10 companies that operate in the same segment as Luoxin Pharmaceutical Group (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Luoxin Pharmaceutical Group
Luoxin Pharmaceutical Group was founded in 2006.
Luoxin Pharmaceutical Group is headquartered in Linyi, China. It is registered at Linyi, Shandong, China.
Annual revenue of Luoxin Pharmaceutical Group is $322.81M as on Dec 31, 2025.
Luoxin Pharmaceutical Group was founded in 2006 in Linyi, China, within the pharmaceutical sector. Operations encompass research and development of drug formulations across therapeutic fields such as gastroenterology, pediatrics, respiratory, and oncology. Manufacturing facilities are utilized for production, while distribution networks facilitate market access. Standards for drug safety and vigilance are consistently applied throughout activities.
Yes, Luoxin Pharmaceutical Group is publicly traded on SZSE under the ticker symbol 002793.
Luoxin Pharmaceutical Group has 1 investor. Key investors include Ally Bridge Group.
Yes. Luoxin Pharmaceutical Group was acquired by Ally Bridge Group in March 2017.